Recent studies suggest that IL-6 and TNF-α are directly produced by the tumoral cells and involved in thedevelopment of lung cancer.The aim of this study was to investigate the concentration of TNF-αand interleukin (IL)-6 in the breath condensate, bronchoalveolar lavage (BAL) and blood of non-small cell lung cancer (NSCLC) patients before treatment.
We enrolled 13 patients with histological evidence of NSCLC (8 men and 5 women, age 61±7 years) and 15 controls with non-malignant lung disease (9 men and 6 women, age 49±8 years). IL6 and TNF-α were measured, in patients and controls, using a specific enzyme immunoassay kit.
Higher concentrations of TNF-α (10.1±3.6 vs 4.2±0.6 pg/ml, 13.4±5.9 vs 5.3±0.9 pg/ml and 11.5±4.8 vs 4.5±0.5 pg/ml) and IL6 (11.2±2.9 vs 2.6±0.6 pg/ml, 11.5±3.1 vs 3.0±0.7 pg/ml and 8.3±1.7 vs 2.5±0.4 pg/ml) were found respectively in exhaled condensate, BAL and plasma of NSCLC patients compared to healthy subjects.
A positive correlation was observed between concentrations of these two markers in the breath condensate, BAL and plasma.
These findings suggest that the measurement of TNF-α and IL-6 in exhaled breath condensate of NSCLC patients could be used for the diagnosis and the monitoring of evolution of this disease.
G. Di Gioia, None.